Summit Therapeutics (SMMT)

Overall impact
C (51)

Commentary

Summit Therapeutics is an average overall performer. With a 'C' rating of 50.6 for overall impact (42nd percentile compared to all companies), Summit Therapeutics ranks 133rd out of 154 industry peers, behind Adamis Pharmaceuticals, Benitec Biopharma, Aquinox Pharmaceuticals and 129 others, and ahead of Evolus, Bausch Health Companies, Theramex and 18 others. On top material causes for Summit Therapeutics's industry (Pharmaceuticals & Biotech), Summit Therapeutics performs well in Child and Maternal Health (90.4 score), Child and Maternal Health (92.6), Equal Pay and Opportunity (87.2) and 1 other cause where it received an 'A' score and performs poorly in Fair Labor Practices (28.6 score), Humane Treatment of Animals (0.0), Sustainable Use of Natural Resources (29.0) and 3 other causes where it received a 'D' or 'F' score.
Impact
Cause SMMT
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
265
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Fl, United States
Share classes
SMMT
Description
Summit Therapeutics Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis. Ivonescimab is currently in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
Material causes
Ethos considers the following causes material for Summit Therapeutics, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.